Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study
Istituto Auxologico Italiano
30 participants
Jun 18, 2019
OBSERVATIONAL
Conditions
Summary
Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Arthropathy occurs in about 75% of acromegalic patients. Any joint may be affected, with the development of osteoarthritis, arthralgia, and an increase in fracture risk. The aims of the present project are to evaluate the dimensions of hands and feet with the 3D scanner method and to perform a quantitative analysis of movement through Gait Analysis technique in de novo patients with acromegaly (group # 1) and in patients with different disease status (group #2).
Eligibility
Inclusion Criteria4
- De novo patients with acromegaly (group # 1), diagnosed according to Endocrine Society guidelines,
- Age equal to18 years or older
- Acromegalic patients with different disease status (group #2)
- Age equal to18 years or older
Exclusion Criteria3
- Cardiorespiratory, neurological or musculoskeletal disorder
- Previous orthopaedic surgery
- Previous lower limbs traumatic injuries
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
De novo patients with acromegaly will undergo medical/surgical therapy of this disease, according to the guidelines of the Endocrine Society. In this population (group #1) morpho-functional examinations together with the evaluation of the stage of the disease, with serum dosage of GH and IGF-1, will be performed at baseline and at months 3, 6 and 12 after initiating the treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05964712